Marketed Products


(ranolazine extended-release tablets)

CORZYNA™ (ranolazine extended-release tablets) is indicated as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies, including beta-blockers and calcium channel blockers.

Product Monograph


(amifampridine phosphate)

FIRDAPSE® (amifampridine) is indicated for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) in adults. FIRDAPSE® should only be prescribed by health professionals who have experience in the treatment of LEMS, are knowledgeable of the efficacy and safety profile of this drug, and are able to discuss benefits/risks of treatment with patients.

To enroll in the FIRDAPSE® Patient Support Program, your physician can complete the enrollment form by filling it out and faxing it to the program administrator at FAX: 1-833-338-0525. The program administrator will then coordinate any required follow-up with you and/or your physician.

For more information about the FIRDAPSE® Patient Support Program, please call 1-833-338-0524 or email

FIRDAPSE® Patient Support Program Enrollment Form

Product Monograph

FIRDAPSE Patient Support Program Enrollment Form

Product Monograph